Piramal Pharma Ltd

Piramal Pharma | 543635

Market Closed

₹195.47

+₹0.00 (+0.74%)

As on 18/11/25, 9:31 PM

Market Cap25,791.4 CR

Current Price₹195.47

High / Low₹283.9 / 181.73

PE Ratio325.36

Book Value₹61.35

Dividend Yield0.06%

ROCE6.43%

ROE9.76%

Face Value₹2.00

Current Vol.16,19,560

Average Vol.12,76,53,456

ISININE0DK501011

PB Ratio3.66

Debt to Equity0.6

Net Profit Margin1

Operating Margin18.06

Stock cgart

Stock Performance

₹2,480₹2,490

₹2,500

Previous CloseToday's Open

₹1,800₹3,000

₹2,500

52W Low52W High

₹2,480Today's Open

₹2,490Previous Close

12,00,000Volume

₹1,80052W Low

₹3,00052W High

Ratios

No data available

About Company

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC
The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market
PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands
Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines
The global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions
In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL)
In October 2020, the Company received growth equity investment from the Carlyle Group

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

;

Technical Indicators

RSI45.94

SMA 20198.57

SMA 50198.33

SMA 100198.51

SMA 200204.88

SMA 10196.91

MACD_12_26_Days-0.78

EMA10Day196.37

EMA20Day197.32

EMA50Day197.75

MACD_12_26_9_Days-0.74

EMA100Day199.90

EMA200Day202.29

Pivot Points

Volume Analysis

Growth Rate

Revenue Growth11.99%

ROE1.14%

EBITDA Margin18.06%

All figures in ₹ Crores

Indicators	2025	2024	2023	2022	2021
Revenue	9,151.18	8,171.16	7,081.55	6,559.10	6,314.90
Interest	421.59	448.49	344.18	198.25	163.45
Expenses	7,706.35	6,974.90	6,453.31	5,609.44	4,886.94
Financing Profit	1,652.57	1,431.14	907.68	1,284.49	1,639.31
Financing Margin %	18%	18%	13%	20%	26%
Other Income	207.74	234.88	279.44	334.83	211.35
Depreciation	816.34	740.57	676.69	586.18	545.04
Profit before tax	414.64	179.29	-120.15	484.98	949.05
Tax %	78%	90%	-55%	22%	12%
Net Profit	91.13	17.82	-186.46	375.96	835.03
EPS in Rs	0.69	0.14	-1.54	3.19	13.30

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

📊

No Data Available

No Block Deals data available for this company.

News

📊

No Information Available

No news available for this company.

Record Date

Corporate Action

Information

Announcement Day

30 Jul 2025

AGM

13 Jun 2025

16 Jul 2025

Final Dividend (₹0.14)

Please refer attachment The Board of Directors has recommended a final dividend of Rs. 0.14/- per Equity Share of Rs. 10/- each for the financial year ended 31st March 2025, which will be paid / dispatched after the 5th Annual General Meeting, subject to the approval of shareholders of the Company. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Wednesday, 16th July, 2025 as the Record Date for the purpose of determining the Members eligible for Final Dividend for the financial year ended 31st March, 2025. If the Final Dividend, as recommended by the Board of Directors, is approved at the AGM, such dividend will be paid/dispatched, subject to deduction of tax at source, after the AGM. (As per BSE Announcement Dated on 13/06/2025)

14 May 2025

26 Jul 2024

AGM

11 Jun 2024

12 Jul 2024

Final Dividend (₹0.11)

The Board of Directors has recommended a final dividend of Rs. 0.11/- per Equity Share of Rs. 10/- each for the financial year ended 31st March 2024, which will be paid / dispatched after the 4th Annual General Meeting, subject to the approval of shareholders of the Company.

10 May 2024

02 Aug 2023

Rights Issue (5:46)

5:46 Rights Issue of Equity Shares

27 Jul 2023

31 Jul 2023

AGM

25 May 2023

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
192	25,528	0	3	32	1	1.00%
1,760	4,22,211	37	5	30	0	20.88%
6,475	1,71,898	69	11	59	0	23.41%
3,793	1,28,372	59	15	43	1	16.60%
1,515	1,22,349	22	4	19	0	19.21%
1,244	1,03,789	18	3	14	0	17.54%
2,047	93,506	22	5	17	0	14.56%
928	93,404	19	4	15	0	19.86%
2,224	91,800	53	6	35	0	14.39%
1,240	72,630	21	2	14	0	10.98%

Showing 10 of 124 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in less than 10 mins*

By proceeding, you agree to all T&C *

Top Gainers

Top Losers

Frequently Asked Questions

What is Share Price of Piramal Pharma Ltd?

The current share price of Piramal Pharma Ltd (Piramal Pharma) is ₹195.47. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Piramal Pharma Ltd?

The Price-to-Earnings (P/E) ratio of Piramal Pharma Ltd is 195.47. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Piramal Pharma Ltd?

Piramal Pharma Ltd has a 52-week high of ₹283.90 and a 52-week low of ₹181.73. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Piramal Pharma Ltd?

Piramal Pharma Ltd offers a dividend yield of 0.07%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Piramal Pharma Ltd?

The Earnings Per Share (EPS) of Piramal Pharma Ltd is ₹-0.27. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Piramal Pharma Ltd?

Piramal Pharma Ltd has a Return on Equity (ROE) of 9.76%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds.